Docetaxel trials for Breast cancer

All Docetaxel trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Docetaxel for Breast cancer

• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
  NCT07441460 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
  NCT06234137 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study for the Adjuvant Treatment of Breast Cancer
  NCT05420467 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study for the Neoadjuvant Treatment of Breast Cancer
  NCT05420454 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
  NCT07518173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
  NCT06348134 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 4 locations
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
  NCT06441890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
  NCT04329065 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  NCT06042569 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 3 locations
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  NCT05883852 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
  NCT04576143 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
  NCT05838066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
  NCT07377643 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
  NCT07797218 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
  NCT07017673 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
  NCT06927180 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
  NCT04947189 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 963 locations
• Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
  NCT07358806 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
  NCT05901428 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
  NCT07220135 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ctDNA in HER2+ EBC Neoadjuvant Treatment
  NCT07335081 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials study Docetaxel for Breast cancer?

29 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.